Stock analysis, trade plans, and proprietary indicators by Trend Edge.
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: October 10, 2017
Headquarters: 601 21st Street, Vero Beach, FL, United States, 32960
Founder-Led: Yes — David Young (President, Research & Development and Founder), Sian Bigora (Chief Development and Regulatory Officer and Founder), Patrick Lin (Chief Business & Strategy Officer and Founder), Wendy Guy (Chief Administrative Officer & Corporate Secretary and Founder)
Key Metrics
Current Price
$2.96
Market Cap
$8.4M
Float
2.5M
Shares Outstanding
2.8M
Price/Sales (TTM)
1,320.06
vs. Analyst Target
+744.6% to analyst PT
Dividend Rate
None
Analyst Target Price
$25.00 (1 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$19.0M
-$882,062
-$14.3M
2021
N/A
-$11.4M
-$875,349
-$10.8M
2022
N/A
-$27.4M
-$874,013
-$19.5M
2023
N/A
-$11.1M
-$222
-$11.5M
2024
N/A
-$11.9M
-$782
-$12.1M
2025
N/A
-$13.6M
-$1,204
-$14.0M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
N/A
-$3.9M
Sep 2025
N/A
-$3.4M
Dec 2025
N/A
-$3.4M
Mar 2026
N/A
-$3.4M
Ownership & Float
Insider Ownership
13.3%
Institutional Ownership
9.1%
Short Float
5.5%
% of All Funds Holding
0.10%
Number of Funds Holding
8
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$2.76
Near-term / short-term trend
Weekly
40-Week SMA
$4.48
Medium-term trend
Weekly
80-Week SMA
$8.73
Cyclical trend (business cycle)
Weekly
200-Week SMA
$226.62
Secular trend (multi-year)
Monthly
10-Month SMA
$4.20
Near-term monthly trend
Monthly
20-Month SMA
$9.26
Medium-term monthly trend
Monthly
40-Month SMA
$81.44
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$6.30
resistance
3.64x
4 months ago
$30.20
resistance
1.06x
16 months ago
Historical Earnings Reactions (30 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.45%
0.00%
36.67%
9.17%
-5.06%
1 Day
-0.57%
0.00%
30.00%
9.47%
-13.16%
1 Week
1.59%
0.00%
43.33%
27.08%
-22.33%
2 Weeks
-5.20%
-8.29%
30.00%
50.83%
-40.00%
1 Month
-0.91%
-9.63%
33.33%
99.05%
-41.29%
Next earnings: May 14, 2026
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-21.0%
8.3%
12
Feb
-0.2%
41.7%
12
Mar
-9.8%
25.0%
12
Apr
-1.6%
23.1%
13
May
-1.1%
41.7%
12
Jun
4.6%
41.7%
12
Jul
19.9%
33.3%
12
Aug
-7.4%
25.0%
12
Sep
4.3%
41.7%
12
Oct
-3.6%
25.0%
12
Nov
-1.5%
25.0%
12
Dec
1.4%
58.3%
12
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.42%
28.2%
575
Tuesday
0.92%
25.4%
631
Wednesday
0.07%
25.8%
628
Thursday
0.18%
25.0%
615
Friday
-0.24%
23.8%
613
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 9.1%
Insider Transactions — Smart Summary
Total insider ownership: 13.3%
Founder-led management: David Young (President, Research & Development and Founder), Sian Bigora (Chief Development and Regulatory Officer and Founder), Patrick Lin (Chief Business & Strategy Officer and Founder), Wendy Guy (Chief Administrative Officer & Corporate Secretary and Founder)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Processa Pharmaceuticals Inc
(PCSA) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.